Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus NUZYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus NUZYRA.
ACHROMYCIN vs NUZYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic